X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jaqbo (zastaprazan citrate) is a next-generation potassium competitive blocker (P-CAB), small molecule drug candidate. It is being evaluated for the treatment of gastroesophageal reflux disease in adults.
Lead Product(s): Zastaprazan Citrate
Therapeutic Area: Gastroenterology Product Name: Jaqbo
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan, Hong Kong and Macau.
Lead Product(s): Zastaprazan
Therapeutic Area: Gastroenterology Product Name: JP 1366
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Livzon Pharmaceutical Group
Deal Size: $127.5 million Upfront Cash: $15.0 million
Deal Type: Acquisition March 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
